Compare Microchip Technology Inc. (MCHP) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Medpace Holdings Inc — how do they compare? Microchip Technology Inc. trades at $75.94 (market cap $41.01B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Microchip Technology Inc. is far larger — about 2.4× Medpace Holdings Inc's market cap, and Microchip Technology Inc. pays a 2.41% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 63 Days and Medpace Holdings Inc for 14 Days on average.
| MCHP | MEDP | |
|---|---|---|
Market Cap | $41.01B | $16.82B |
Volume | 9,972,516 | 223,093 |
Sector | Technology | Health |
52-Week High | $102.97 | $630.19 |
52-Week Low | $49.02 | $393.42 |
Typical Hold Time | 63 Days | 14 Days |
Enterprise Value | $46.13B | $16.44B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $75.55, down 3.17% over the past day, with a bearish technical signal from moving averages. The company reported a net loss of -$500K in 2025 despite beating EPS estimates in recent quarters, though revenue declined to $4.40B. Analyst consensus is strongly bullish with a $110.50 price target, and recent news highlights expansion in Ethernet and 48V power portfolios alongside the acquisition of Hailo to bolster edge AI capabilities.
MCHP faces near-term headwinds from profitability pressures and high debt, but long-term growth is supported by AI infrastructure demand and strategic expansions. Investment opportunities exist if operational improvements and market trends materialize, though risks include competitive intensity and execution challenges in a cyclical semiconductor market.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
